Colorectal Cancer Trial, Recruiting (NCT06434896)

Colorectal Cancer Trial, Recruiting NCT06434896 Sponsor: UMC Utrecht Condition: Colorectal Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06434896 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Colorectal Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 or older
People who have given consent to participate in the PLCRC registry, including agreement to extra blood draws, use of tissue samples for research, and being contacted about future research studies
People already enrolled in a related observational study called PLCRC-MEDOCC
People who have been diagnosed with stage II colon cancer, confirmed by laboratory testing of tissue
People whose treating doctor considers them well enough to receive a combination chemotherapy treatment involving two types of drugs (fluoropyrimidine and oxaliplatin)

Who may not be able to join:

People whose treating doctor has already recommended they receive chemotherapy after surgery
People who have had another cancer in the past 5 years, unless it was a treated early-stage (non-invasive) cancer or a non-melanoma skin cancer
People whose surgery did not fully remove the tumour
People who have a medical reason why they cannot receive either of the two chemotherapy drugs used in this trial
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +316 46 91 95 66

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06434896

Sponsor: UMC Utrecht

Phase: Not Applicable

Status: Recruiting

Condition: Colorectal Cancer

Trial contact: +316 46 91 95 66

More information: https://clinicaltrials.gov/study/NCT06434896

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 or older
People who have given consent to participate in the PLCRC registry, including agreement to extra blood draws, use of tissue samples for research, and being contacted about future research studies
People already enrolled in a related observational study called PLCRC-MEDOCC
People who have been diagnosed with stage II colon cancer, confirmed by laboratory testing of tissue
People whose treating doctor considers them well enough to receive a combination chemotherapy treatment involving two types of drugs (fluoropyrimidine and oxaliplatin)

Who may not be able to join:

People whose treating doctor has already recommended they receive chemotherapy after surgery
People who have had another cancer in the past 5 years, unless it was a treated early-stage (non-invasive) cancer or a non-melanoma skin cancer
People whose surgery did not fully remove the tumour
People who have a medical reason why they cannot receive either of the two chemotherapy drugs used in this trial
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

UMC Utrecht

Registry

ClinicalTrials.gov

Start date

5 March 2020

Est. completion

1 December 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Proportion of patients starting with adjuvant chemotherapy after detection of ctDNA in their blood.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov